Jennifer A. Quinn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jennifer A. Quinn has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Allan H. Friedman
Departments of Surgery (J.A.Q., S.X.J., D.A.R., A.D., J.J.V., J.N.R., S.G., A.H.F., D.D.B., J.H.S., A.W., H.S.F.), Pathology (D.D.B., R.E.M.), and Biostatistics and Bioinformatics (J.E.H.), Duke University Medical Center, Durham, NC, USA
5 shared publicationsDarell D. Bigner
Departments of Surgery (J.A.Q., S.X.J., D.A.R., A.D., J.J.V., J.N.R., S.G., A.H.F., D.D.B., J.H.S., A.W., H.S.F.), Pathology (D.D.B., R.E.M.), and Biostatistics and Bioinformatics (J.E.H.), Duke University Medical Center, Durham, NC, USA
5 shared publicationsDavid A. Reardon
Departments of Surgery (J.A.Q., S.X.J., D.A.R., A.D., J.J.V., J.N.R., S.G., A.H.F., D.D.B., J.H.S., A.W., H.S.F.), Pathology (D.D.B., R.E.M.), and Biostatistics and Bioinformatics (J.E.H.), Duke University Medical Center, Durham, NC, USA
5 shared publicationsHenry S. Friedman
Departments of Surgery (J.A.Q., S.X.J., D.A.R., A.D., J.J.V., J.N.R., S.G., A.H.F., D.D.B., J.H.S., A.W., H.S.F.), Pathology (D.D.B., R.E.M.), and Biostatistics and Bioinformatics (J.E.H.), Duke University Medical Center, Durham, NC, USA
5 shared publicationsJames E. Herndon
Departments of Surgery (J.A.Q., S.X.J., D.A.R., A.D., J.J.V., J.N.R., S.G., A.H.F., D.D.B., J.H.S., A.W., H.S.F.), Pathology (D.D.B., R.E.M.), and Biostatistics and Bioinformatics (J.E.H.), Duke University Medical Center, Durham, NC, USA
5 shared publications- John H. Sampson
Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, USA
5 shared publications
Latest Publications
- Open Access
- 1 October 2009
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 11 (5) , 556-561
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma
This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tole
- 1 October 2009
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 11 (5) , 556-561
Open AccessPhase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma
This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tole
- 1 October 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (28) , 7178-7187
Phase I Trial of Temozolomide Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma
Purpose: We conducted a two-phase clinical trial in patients with progressive malignant glioma (MG). The first phase of this trial was designed to determine the dose of O6-BG effective in producing complete depletion of tumor AGT activity for 48 hours. The second phase of the trial was designed to define the maximum tolerated dose (MTD) of a single dose of temozolomide when combined with O6-BG. In addition, plasma concentrations of O6-BG and O6-benzyl-8-oxoguanine were evaluated after O6-BG. Patients and Methods: For our first phase of the clinical trial, patients were scheduled to undergo craniotomy for AGT determination after receiving a 1-hour O6-BG infusion at 120 mg/m2 followed by a continuous infusion at an initial dose of 30 mg/m2/d for 48 hours. The dose of the continuous infusion of O6-BG escalated until tumor AGT was depleted. Once the O6-BG dose was established a separate group of patients was enrolled in the second phase of clinical trial, in which temozolomide, administered as a single dose at the end of the 1-hour O6-BG infusion, was escalated until the MTD was determined. Results: The O6-BG dose found to be effective in depleting tumor AGT activity at 48 hours was an IV bolus of 120 mg/m2 over 1 hour followed by a continuous infusion of 30 mg/m2/d for 48 hours. On enrolling 38 patients in six dose levels of temozolomide, the MTD was established at 472 mg/m2 with dose-limiting toxicities limited to myelosuppression. Conclusion: This study provides the foundation for a phase II trial of O6-BG plus temozolomide in temozolomide-resistant MG.
- 1 October 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (28) , 7178-7187
Phase I Trial of Temozolomide Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma
Purpose: We conducted a two-phase clinical trial in patients with progressive malignant glioma (MG). The first phase of this trial was designed to determine the dose of O6-BG effective in producing complete depletion of tumor AGT activity for 48 hours. The second phase of the trial was designed to define the maximum tolerated dose (MTD) of a single dose of temozolomide when combined with O6-BG. In addition, plasma concentrations of O6-BG and O6-benzyl-8-oxoguanine were evaluated after O6-BG. Patients and Methods: For our first phase of the clinical trial, patients were scheduled to undergo craniotomy for AGT determination after receiving a 1-hour O6-BG infusion at 120 mg/m2 followed by a continuous infusion at an initial dose of 30 mg/m2/d for 48 hours. The dose of the continuous infusion of O6-BG escalated until tumor AGT was depleted. Once the O6-BG dose was established a separate group of patients was enrolled in the second phase of clinical trial, in which temozolomide, administered as a single dose at the end of the 1-hour O6-BG infusion, was escalated until the MTD was determined. Results: The O6-BG dose found to be effective in depleting tumor AGT activity at 48 hours was an IV bolus of 120 mg/m2 over 1 hour followed by a continuous infusion of 30 mg/m2/d for 48 hours. On enrolling 38 patients in six dose levels of temozolomide, the MTD was established at 472 mg/m2 with dose-limiting toxicities limited to myelosuppression. Conclusion: This study provides the foundation for a phase II trial of O6-BG plus temozolomide in temozolomide-resistant MG.
- Open Access
- 1 April 2004
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 6 (2) , 145-153
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma
Irinotecan is a topoisomerase I inhibitor previously shown to be active in the treatment of malignant glioma. We now report the results of a phase 1
- 1 April 2004
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 6 (2) , 145-153
Open AccessPhase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma
Irinotecan is a topoisomerase I inhibitor previously shown to be active in the treatment of malignant glioma. We now report the results of a phase 1
- 15 February 2003
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (4) , 646-651
Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma
Purpose: Temozolomide (Temodar; Schering-Plough Corp, Kenilworth, NJ) is an imidazole tetrazinone that undergoes chemical conversion to the active methylating agent 5-(3-methyltriazen-1yl)imidazole-4-carboximide under physiologic conditions. Previous studies have confirmed activity of Temodar in the treatment of progressive and newly diagnosed malignant gliomas. We have extended these results, and now we report results of a phase II trial of Temodar for patients with progressive, low-grade glioma. Patients and Methods: Temodar was administered orally once a day for five consecutive days (in a fasting state) at a starting dose of 200 mg/m2/d. Treatment cycles were repeated every 28 days following the first daily dose of Temodar. Response criteria used a combination of magnetic resonance imaging and physical examination to evaluate activity. Results: Forty-six patients with low-grade glioma have been treated to date. The objective response rate was 61% (24% complete response and 37% partial response), with an additional 35% of patients having stable disease. Median progression-free survival (PFS) was 22 months (95% confidence interval [CI], 15 to ∞ months) with a 6-month PFS of 98% (95% CI, 94% to 100%) and a 12-month PFS of 76% (95% CI, 63% to 92%). Toxicity observed during the study was limited to only six patients. Three patients experienced grade 3 neutropenia, with a duration greater than 3 weeks in one patient, and two patients experienced grade 3 thrombocytopenia. One patient experienced ≥ grade 4 toxicity, with intracerebral hemorrhage, neutropenia, thrombocytopenia, sepsis, and death. Conclusion:Initial results indicate that Temodar may be active in the treatment of low-grade glioma, and thus, further evaluation of this agent in the treatment of these tumors is warranted.
- 15 February 2003
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (4) , 646-651
Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma
Purpose: Temozolomide (Temodar; Schering-Plough Corp, Kenilworth, NJ) is an imidazole tetrazinone that undergoes chemical conversion to the active methylating agent 5-(3-methyltriazen-1yl)imidazole-4-carboximide under physiologic conditions. Previous studies have confirmed activity of Temodar in the treatment of progressive and newly diagnosed malignant gliomas. We have extended these results, and now we report results of a phase II trial of Temodar for patients with progressive, low-grade glioma. Patients and Methods: Temodar was administered orally once a day for five consecutive days (in a fasting state) at a starting dose of 200 mg/m2/d. Treatment cycles were repeated every 28 days following the first daily dose of Temodar. Response criteria used a combination of magnetic resonance imaging and physical examination to evaluate activity. Results: Forty-six patients with low-grade glioma have been treated to date. The objective response rate was 61% (24% complete response and 37% partial response), with an additional 35% of patients having stable disease. Median progression-free survival (PFS) was 22 months (95% confidence interval [CI], 15 to ∞ months) with a 6-month PFS of 98% (95% CI, 94% to 100%) and a 12-month PFS of 76% (95% CI, 63% to 92%). Toxicity observed during the study was limited to only six patients. Three patients experienced grade 3 neutropenia, with a duration greater than 3 weeks in one patient, and two patients experienced grade 3 thrombocytopenia. One patient experienced ≥ grade 4 toxicity, with intracerebral hemorrhage, neutropenia, thrombocytopenia, sepsis, and death. Conclusion:Initial results indicate that Temodar may be active in the treatment of low-grade glioma, and thus, further evaluation of this agent in the treatment of these tumors is warranted.
- 1 May 2002
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (9) , 2277-2283
Phase II Trial of Carmustine Plus O6-Benzylguanine for Patients With Nitrosourea-Resistant Recurrent or Progressive Malignant Glioma
PURPOSE: We conducted a phase II trial of carmustine (BCNU) plus the O6-alkylguanine-DNA alkyltransferase inhibitor O6-benzylguanine (O6-BG) to define the activity and toxicity of this regimen in the treatment of adults with progressive or recurrent malignant glioma resistant to nitrosoureas. PATIENTS AND METHODS: Patients were treated with O6-BG at an intravenous dose of 120 mg/m2 followed 1 hour later by 40 mg/m2 of BCNU, with cycles repeated at 6-week intervals. RESULTS: Eighteen patients were treated (15 with glioblastoma multiforme, two with anaplastic astrocytoma, and one with malignant glioma). None of the 18 patients demonstrated a partial or complete response. Two patients exhibited stable disease for 12 weeks before their tumors progressed. Three patients demonstrated stable disease for 6, 12, and 18 weeks before discontinuing therapy because of hematopoietic toxicity. Twelve patients experienced reversible ≥ grade 3 hematopoietic toxicity. There was no difference in half-lives (0.56 ± 0.21 hour v 0.54 ± 0.20 hour) or area under the curve values (4.8 ± 1.7 μg/mL/h v 5.0 ± 1.3 μg/mL/h) of O6-BG for patients receiving phenytoin and those not treated with this drug. CONCLUSION: These results indicate that O6-BG plus BCNU at the dose schedule used in this trial is unsuccessful in producing tumor regression in patients with nitrosourea-resistant malignant glioma, although stable disease was seen in five patients for 6, 12, 12, 12, and 18 weeks. Future use of this approach will require strategies to minimize dose-limiting toxicity of BCNU such as regional delivery or hematopoietic stem-cell protection.
- 1 May 2002
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (9) , 2277-2283
Phase II Trial of Carmustine Plus O6-Benzylguanine for Patients With Nitrosourea-Resistant Recurrent or Progressive Malignant Glioma
PURPOSE: We conducted a phase II trial of carmustine (BCNU) plus the O6-alkylguanine-DNA alkyltransferase inhibitor O6-benzylguanine (O6-BG) to define the activity and toxicity of this regimen in the treatment of adults with progressive or recurrent malignant glioma resistant to nitrosoureas. PATIENTS AND METHODS: Patients were treated with O6-BG at an intravenous dose of 120 mg/m2 followed 1 hour later by 40 mg/m2 of BCNU, with cycles repeated at 6-week intervals. RESULTS: Eighteen patients were treated (15 with glioblastoma multiforme, two with anaplastic astrocytoma, and one with malignant glioma). None of the 18 patients demonstrated a partial or complete response. Two patients exhibited stable disease for 12 weeks before their tumors progressed. Three patients demonstrated stable disease for 6, 12, and 18 weeks before discontinuing therapy because of hematopoietic toxicity. Twelve patients experienced reversible ≥ grade 3 hematopoietic toxicity. There was no difference in half-lives (0.56 ± 0.21 hour v 0.54 ± 0.20 hour) or area under the curve values (4.8 ± 1.7 μg/mL/h v 5.0 ± 1.3 μg/mL/h) of O6-BG for patients receiving phenytoin and those not treated with this drug. CONCLUSION: These results indicate that O6-BG plus BCNU at the dose schedule used in this trial is unsuccessful in producing tumor regression in patients with nitrosourea-resistant malignant glioma, although stable disease was seen in five patients for 6, 12, 12, 12, and 18 weeks. Future use of this approach will require strategies to minimize dose-limiting toxicity of BCNU such as regional delivery or hematopoietic stem-cell protection.